Community hub
Recent from talks
Knowledge base stats:
Talk channels stats:
Members stats:
Angela Hartley Brodie
Angela Hartley Brodie (28 September 1934 – 7 June 2017) was a British biochemist who pioneered development of steroidal aromatase inhibitors in cancer research. Born in Lancashire (now Greater Manchester), Brodie studied chemical pathology to a doctoral level in Sheffield and was awarded a fellowship sponsored by National Institutes of Health. After 17 years of working in Shrewsbury, Massachusetts on oral contraceptives with Harry Brodie, whom she married, she switched her research focus to the effects of the oestrogen-producing enzyme, aromatase, on breast cancer.
Brodie managed to get an aromatase inhibitor into a limited clinical trial in breast cancer patients in London, which had such a profound effect that it led to further Novartis-sponsored trials, and in turn to the development of formestane, the first aromatase inhibitor, eventually marketed in 1994.
Brodie's work has been hailed "as among the most important contributions to cancer cure".
Brodie was born Angela Hartley on 28 September 1934 in Oldham, Lancashire, England. Her father, Herbert Hartley, was an industrial chemist working in polyurethanes who inspired her interest in science. Brodie was educated at a Quaker boarding school before studying at University of Sheffield, where she earned a degree in biochemistry.
After leaving university, she took a job in a blood bank before finding a laboratory position as a research assistant in the Department of Hormone Research at Manchester's Christie Hospital Whilst there, she concentrated on oestrogen-dependent breast cancer for two years before joining the University of Manchester to study for her doctorate.
In 1961, Brodie received her PhD in chemical pathology from the University of Manchester, where her research focussed primarily on the hormone aldosterone.
As a result of her doctorate, she was awarded a National Institutes of Health sponsored, 1-year post-doctoral training fellowship, at Clark University and the Worcester Foundation for Experimental Biology in Shrewsbury, Massachusetts. She researched at Worcester Foundation between 1962 and 1979. There, she worked initially on the oral contraceptive usage of aldosterone, alongside a number of scientists. This included Harry Brodie, whom she married in 1964, and Mika Hayano, who died of breast cancer in her 40s. Over the next few years, Brodie took time away from laboratory work when her two sons, Mark and John Hartley Brodie (1970–2006) were born.
When Brodie returned to work in 1971, she joined her husband's lab as staff scientist, moving into breast cancer research, especially its link with oestrogen and an enzyme that produces it, aromatase. They developed several steroidal aromatase inhibitors, she focused on 4-OHA.
Hub AI
Angela Hartley Brodie AI simulator
(@Angela Hartley Brodie_simulator)
Angela Hartley Brodie
Angela Hartley Brodie (28 September 1934 – 7 June 2017) was a British biochemist who pioneered development of steroidal aromatase inhibitors in cancer research. Born in Lancashire (now Greater Manchester), Brodie studied chemical pathology to a doctoral level in Sheffield and was awarded a fellowship sponsored by National Institutes of Health. After 17 years of working in Shrewsbury, Massachusetts on oral contraceptives with Harry Brodie, whom she married, she switched her research focus to the effects of the oestrogen-producing enzyme, aromatase, on breast cancer.
Brodie managed to get an aromatase inhibitor into a limited clinical trial in breast cancer patients in London, which had such a profound effect that it led to further Novartis-sponsored trials, and in turn to the development of formestane, the first aromatase inhibitor, eventually marketed in 1994.
Brodie's work has been hailed "as among the most important contributions to cancer cure".
Brodie was born Angela Hartley on 28 September 1934 in Oldham, Lancashire, England. Her father, Herbert Hartley, was an industrial chemist working in polyurethanes who inspired her interest in science. Brodie was educated at a Quaker boarding school before studying at University of Sheffield, where she earned a degree in biochemistry.
After leaving university, she took a job in a blood bank before finding a laboratory position as a research assistant in the Department of Hormone Research at Manchester's Christie Hospital Whilst there, she concentrated on oestrogen-dependent breast cancer for two years before joining the University of Manchester to study for her doctorate.
In 1961, Brodie received her PhD in chemical pathology from the University of Manchester, where her research focussed primarily on the hormone aldosterone.
As a result of her doctorate, she was awarded a National Institutes of Health sponsored, 1-year post-doctoral training fellowship, at Clark University and the Worcester Foundation for Experimental Biology in Shrewsbury, Massachusetts. She researched at Worcester Foundation between 1962 and 1979. There, she worked initially on the oral contraceptive usage of aldosterone, alongside a number of scientists. This included Harry Brodie, whom she married in 1964, and Mika Hayano, who died of breast cancer in her 40s. Over the next few years, Brodie took time away from laboratory work when her two sons, Mark and John Hartley Brodie (1970–2006) were born.
When Brodie returned to work in 1971, she joined her husband's lab as staff scientist, moving into breast cancer research, especially its link with oestrogen and an enzyme that produces it, aromatase. They developed several steroidal aromatase inhibitors, she focused on 4-OHA.